Overall, our results indicate that current biomarkers suggested for predicting response to glutaminase inhibition do not fully capture the complexity of glutamine metabolism in cancer and that the response to glutaminase inhibitors depends on the individual tumor’s ability to compensate for reduced glutamate availability. Here, GLS is linked to cancer.